

This article was downloaded by: [University of Windsor]

On: 26 September 2013, At: 12:14

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Food and Agricultural Immunology

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/cfai20>

4-arylcoumarin inhibits immediate-type allergy

Thongchai Taechowisan^a, Chunhua Lu^b, Yuemao Shen^c & Saisamorn Lumyong^d

^a Department of Microbiology, Faculty of Science, Silpakorn University, Nakorn Pathom, Thailand

^b School of Life Sciences, Xiamen University, Xiamen, China

^c Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming, China

^d Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand

Published online: 30 Nov 2007.

To cite this article: Thongchai Taechowisan, Chunhua Lu, Yuemao Shen & Saisamorn Lumyong (2007) 4-arylcoumarin inhibits immediate-type allergy, Food and Agricultural Immunology, 18:3-4, 203-211, DOI: [10.1080/09540100701788636](https://doi.org/10.1080/09540100701788636)

To link to this article: <http://dx.doi.org/10.1080/09540100701788636>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

4-arylcoumarin inhibits immediate-type allergy

THONGCHAI TAECHOWISAN¹, CHUNHUA LU²,
YUEMAO SHEN³, & SAISAMORN LUMYONG⁴

¹Department of Microbiology, Faculty of Science, Silpakorn University, Nakorn Pathom, Thailand, ²School of Life Sciences, Xiamen University, Xiamen, China, ³Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming, China, and ⁴Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand

(Received 26 July 2007; accepted 5 November 2007)

Abstract

This study was undertaken to investigate the effect of 4-arylcoumarin (5,7-dimethoxy-4-*p*-methoxyphenylcoumarin; MPC) on immediate-type allergic reaction and inflammatory cytokine secretion. MPC inhibited compound 48/80-induced systemic reactions in mice. When MPC was given as a pretreatment at concentrations ranging from 0.001 to 1 g/kg, the serum histamine levels induced by compound 48/80 were reduced in a dose-dependent manner. In addition, MPC also inhibited the passive cutaneous anaphylaxis activated by anti-dinitrophenyl (DNP) IgE antibody dose dependently. Furthermore, MPC decreased the phorbol 12-myristate 13-acetate plus calcium ionophore A23187-stimulated tumor necrosis factor- α and interleukin-6 secretion in human mast cells. These results indicate that MPC may be beneficial in the treatment of immediate-type allergic reactions.

Keywords: 4-arylcoumarins, immediate-type allergic reaction, mast cells, tumor necrosis factor- α , interleukin-6.

Introduction

Mast cells are important mediators of inflammatory responses such as allergy and hypersensitivity. Immediate-type hypersensitivity (anaphylaxis), an acute systemic allergic reaction, is mediated by histamine released in response to the antigen cross-linking of immunoglobulin E (IgE) bound to the Fc ϵ receptor I (Fc ϵ RI) on mast cells. Mast cell activation causes the process of degranulation, which results in the releasing of mediators, such as histamine and an array of inflammatory cytokines (Metcalf et al. 1981; Lagunoff et al. 1983; Church et al. 1997). Among the inflammatory substances released from mast cells, histamine remains the best-characterized and most potent vasoactive mediator implicated in the acute phase of immediate hypersensitivity (Petersen et al. 1996). Mast cell activation is initiated upon interaction of multivalent antigen with its specific IgE antibody attached to the cell membrane via Fc ϵ RI (Metzger et al. 1986; Alber et al. 1991). Anti-dinitrophenyl (DNP) IgE antibody and

Correspondence: Thongchai Taechowisan, Department of Microbiology, Faculty of Science, Silpakorn University, Nakorn Pathom 73000, Thailand. Tel: +66 34 243429 ext. 8809. Fax: +66 34 273046. E-mail: tthongch@su.ac.th

antigen have been established to induce passive cutaneous anaphylaxis (PCA) reactions as a typical *in vitro* model for immediate hypersensitivity. Mast cell degranulation can also be elicited by non-immunologic stimulators, such as neuropeptides, basic compounds, complement components, and certain drugs (Lagunoff et al. 1983). Compound 48/80 and polymers of basic amino acids, such as substance P, are some of the most potent stimulators of mast cells. Thus, an appropriate amount of compound 48/80 has been used as a direct and convenient reagent to study the mechanism of anaphylaxis (Ennis et al. 1980). Activated mast cells can produce histamine, as well as a wide variety of other inflammatory mediators, such as eicosanoids, proteoglycans, proteases, and several pro-inflammatory and chemotactic cytokines, such as tumor necrosis factor (TNF- α), interleukins (IL-6, IL-4, IL-13), and transforming growth factor- β (Burd et al. 1989; Plaut et al. 1989; Galli et al. 1991; Bradding et al. 1993). Therefore, modulation of secretion of these cytokines from mast cells can provide a useful therapeutic strategy for allergic inflammatory disease. In experimental allergic models, disodium cromoglycate (DSCG; a mast cell stabilizer) shows an obvious inhibitory effect on the immediate-type allergic reactions. This inhibitory effect is thought to be based on the inhibition of the mediator from mast cells (Thomson & Evans 1973; Wells & Mann 1983). As part of our continuing search for biologically active anti-allergenic agents from the endophytic actinomycetes, 5,7-dimethoxy-4-*p*-methoxyphenylcoumarin (Figure 1), the major active ingredients from the culture filtrate of *Streptomyces aureofaciens* CMUAc130 (Taechowisan et al. 2005) showed anti-inflammatory activity (Taechowisan et al. 2007). In the present study, we evaluated the effect of 5,7-dimethoxy-4-*p*-methoxyphenylcoumarin (MPC) on compound 48/80-induced systemic reaction and anti-dinitrophenyl (DNP) IgE antibody-induced local allergic reaction. Additionally, the effect of 5,7-dimethoxy-4-*p*-methoxyphenylcoumarin on phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore A23187 (A23187)-induced TNF- α and IL-6 secretion in human mast cells (HMC-1) was also investigated.

Materials and methods

Preparation of 4-arylcoumarin

Streptomyces aureofaciens CMUAc130 was isolated from the root tissues of *Zingiber officinale* by the surface-sterilization technique (Taechowisan et al. 2003). Identification of the isolate to species level was based on morphological, cultural, physiological and




Figure 1. Chemical structure of 5,7-dimethoxy-4-*p*-methoxyphenylcoumarin.

biochemical characteristics, and 16S rDNA gene sequencing as described by Taechowisan and Lumyong (2003). Solid medium for sporulation used in this study was International *Streptomyces* Project Medium 4 (ISP-4) and the liquid medium used for fermentation was ISP-2 (Shirling & Gottlieb 1966). Large-scale fermentation, crude extraction and purification of the compounds were carried out following the methods of Taechowisan et al. (2005).

Structure elucidation of the compounds

The structure of the active compound has been identified using NMR and mass spectral data. The melting point of the compounds was determined on a Buchi-540 melting point apparatus. Optical rotations were measured on a Perkin-Elmer 241 polarimeter, IR spectra on a Perkin-Elmer 1 spectrometer, ^1H and ^{13}C NMR spectra on a Bruker DRX 500 spectrometer, and EI-MS and FAB-MS, respectively, on a Hewlett-Packard 5989 B and a Finnigan/Thermo Quest Mat 95 XL mass spectrometer.

Compound 48/80-induced systemic reaction

Male ICR mice were purchased from National Laboratory Animal Center (Mahidol University, Thailand). Mice were given an intraperitoneal injection of 0.008 g/kg body weight (BW) of the mast cell degranulator, compound 48/80 (Sigma Chemical Co., USA). MPC was dissolved in saline and administered intraperitoneally (range: 0.001–1 g/kg BW) 1 h before the injection of compound 48/80 ($n=10/\text{group}$). In the time-dependent experiment, MPC (1 g/kg) was administered intraperitoneally at 5, 10 and 20 min after injection of compound 48/80 ($n=10/\text{group}$). Mortality was monitored for 1 h after induction of anaphylactic shock. After the mortality test, blood was obtained from the heart of each mouse.

Passive cutaneous anaphylaxis reaction

The mice were injected intradermally with 0.5 μg of anti-DNP IgE (Sigma Chemical Co.) into each of two dorsal skin sites that had been shaved 48 h earlier. The sites were outlined with a water-insoluble red marker. After 48 h, each mouse was received an injection of 1 μg of DNP-human serum albumin (DNP-HAS) (Sigma Chemical Co.) in PBS containing 4% Evans blue (1:4) via the tail vein. MPC (0.01–1 g/kg BW) was intraperitoneally administered 1 h before the challenge. Some 30 min after the challenge, the mice were sacrificed and the dorsal skin was removed for measurement of the pigment area. The amount of dye was determined colorimetrically after extraction with 1 ml of 1 M KOH and 9 ml of a mixture of acetone and phosphoric acid (5:13) based on the previous report (Katayama et al. 1978). The absorbent intensity of the extraction was measured at 620 nm using a spectrophotometer.

Preparation of plasma and histamine determination

The blood was centrifuged at $400 \times g$ for 10 min. The plasma was withdrawn and histamine content was measured by the *o*-phthalaldehyde (Sigma Chemical Co.)

spectrofluorometric procedure (Shore et al. 1959). The fluorescent intensity was measured at a 438-nm emission and a 353-nm excitation using a spectrofluorometer.

Assay of TNF- α and IL-6 secretion

TNF- α and IL-6 secretion was measured by modification of an enzyme-linked immunosorbent assay (ELISA) as described previously (Scuderi et al. 1986). HMC-1 cells were cultured with α -minimal essential medium (α -MEM; Sigma Chemical Co.) plus 10% FBS and resuspended in Tyrode buffer A. The cells were sensitized with 20 nM of phorbol 12-myristate 13-acetate (PMA) (Sigma Chemical Co.) plus 1 μ M of calcium ionophore A23187 (A23187) (Sigma Chemical Co.) for 6 h in the absence or presence of MPC. The ELISA was performed by coating 96-well plates with 6.25 ng/well of monoclonal antibody with specificity for TNF- α and IL-6, respectively. Before use and between subsequent steps in the assay, the coated plates were washed twice with PBS containing 0.05% Tween-20 and twice with PBS alone. For the standard curve, rTNF- α and rIL-6 (R&D Systems Inc., USA) were added to serum previously determined to be negative to endogenous TNF- α and IL-6. After exposure to the medium, the assay plates were exposed sequentially to biotinylated anti-human TNF- α and IL-6, 2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid (ABTS) (Sigma Chemical Co.) tablets substrates. Optical density reading was made within 10 min of the addition of the substrate with a 405-nm filter.

Statistical analysis

Statistical analyses were performed using SPSS for Windows, version 11.01 (SPSS Inc., Chicago, IL, USA). Treatment effects were analyzed using one-way ANOVA, followed by Duncan's multiple range tests. A p value ≤ 0.05 was used to indicate significance.

Results

MPC inhibits compound 48/80-induced systemic reaction

To assess the contribution of MPC in systemic reaction, an *in vivo* model of systemic anaphylaxis was used. Compound 48/80 (0.008 g/kg) was used as a model of induction of systemic fatal allergic reaction. After the intraperitoneal injection of compound 48/80, the mice were monitored for 1 h, after which the mortality rate was determined. Compound 48/80 induced fatal shock in 100% of animals. When PBS was administered intraperitoneally at concentrations ranging from 0.001 to 1 g/kg BW for 1 h, the mortality with compound 48/80 was dose-dependently reduced (Table I). In addition, the mortality of mice administered with MPC (1 g/kg) 5, 10, and 20 min after compound 48/80 injection increased time-dependently (Table II). In this same *in vivo* experiment, DSCG also had an inhibitory effect on compound 48/80-induced systemic reaction.

MPC inhibits compound 48/80-induced plasma histamine release

The effect of MPC on compound 48/80-induced plasma histamine release was investigated. MPC (0.001–1 g/kg BW) was administered 1 h before the compound

Table I. Effect of MPC on compound 48/80-induced systemic allergic reaction.

Treatment (g/kg BW)	Compound 48/80 (0.008 g/kg BW)	Mortality (%)	
		MPC	DSCG
None (saline)	+	100	100
0.001	+	100	100
0.005	+	100	100
0.01	+	80	100
0.05	+	50	70
0.1	+	30	40
0.5	+	10	0
1	+	0	0
1	—	0	0

Groups of mice ($n=10/\text{group}$) were intraperitoneally pretreated with 200 μl of saline or MPC or DSCG. Various doses of MPC or DSCG were given 1 h before the intraperitoneal injection of compound 48/80. Mortality (%) within 1 h following compound 48/80 injection is represented as the number of dead mice $\times$ 100/total number of experimental mice.

48/80 injection. MPC (0.05–1 g/kg) and DSCG (1 g/kg) significantly inhibited compound 48/80-induced plasma histamine release (Figure 2).

MPC inhibits the IgE-mediated local allergic reaction

PCA is one of the most important *in vivo* models of anaphylaxis in local allergic reactions and, in part, mediated by histamine in the blood stream (Mican et al. 1992). Local extravasation is induced by a local injection of anti-DNP IgE followed by an intravenous antigenic challenge. Intraperitoneal administration of MPC (0.1–1 g/kg) and DSCG (1 g/kg) showed a marked inhibition rate in PCA reaction (Figure 3).

MPC inhibits pro-inflammatory cytokine secretion in HMC-1 cells

We examined whether MPC could regulate pro-inflammatory cytokines, such as TNF- α and IL-6 in HMC-1 cells. HMC-1 cell line is a useful cell for studying cytokine activation pathway (Sillaber et al. 1993; Moller et al. 1998). Stimulation of HMC-1 cells with PMA plus A23187 induced the secretion of both cytokines. However, pretreatment with MPC decreased PMA plus A23187-induced TNF- α and IL-6 secretion (Figures 4 and 5).

Table II. Time-dependent effect of MPC on compound 48/80-induced systemic allergic reaction.

Treatment (g/kg BW)	Time (min)	Compound 48/80 (0.008 g/kg BW)	Mortality (%)	
			MPC	DSCG
None (saline)		+	100	100
1	5	+	30	0
1	10	+	70	50
1	20	+	100	100

Groups of mice ($n=10/\text{group}$) were intraperitoneally pretreated with 200 μl of saline or MPC or DSCG. MPC or DSCG (1 g/kg) was given at 5, 10, and 20 min after the intraperitoneal injection of compound 48/80. Mortality (%) within 1 h following compound 48/80 injection is represented as the number of dead mice $\times$ 100/total number of experimental mice.




Figure 2. Effect of MPC on compound 48/80-induced plasma histamine release. Groups of mice ($n=10$ group) were intraperitoneally pretreated with 200 μ l of saline or MPC or DSCG. MPC or DSCG was given 1 h before the intraperitoneal injection of compound 48/80. Each date represents the mean $\pm$ SEM of three independent experiments. * $p < 0.05$; significantly different from the saline value.

Discussion

Several reports established that stimulation of mast cells with compound 48/80 or IgE initiates the activation of signal-transduction pathway, which leads to histamine release. Many studies have shown that compound 48/80 and other polybasic compounds are able to activate G-proteins (Mousli et al. 1990a,b; Chahdi et al. 2000). Tasaka et al. (1986) reported that compound 48/80 increases the permeability of the lipid bilayer membrane by causing a perturbation of the membrane. These




Figure 3. Effect of MPC on the PCA reaction. MPC or DSCG was intraperitoneally administered 1 h prior to the challenge with antigen. Each date represents the mean $\pm$ SEM of three independent experiments. * $p < 0.05$; significantly different from the saline value.




Figure 4. Effect of MPC on the TNF- α secretion. PMA plus A23187-stimulated HMC-1 cells were incubated for 8 h in the absence or presence of MPC. TNF- α secreted into the medium is presented as the mean $\pm$ SEM of three independent experiments. * $p < 0.05$; significantly different from the PMA+A23187 value.

reports indicate that the increase in membrane permeability may be an essential trigger for the release of the mediator from mast cells. In this sense, anti-allergic agents with a membrane-stabilizing action may be desirable. The results of our study demonstrated that MPC has anti-allergic properties. MPC and DSCG inhibited compound 48/80-induced systemic reaction and anti-DNP IgE-mediated local allergic reaction. These results indicate that mast cell-mediated immediate-type allergic reactions are inhibited by MPC. Taken together, we could speculate that MPC might stabilize the lipid bilayer membrane, thus preventing the perturbation induced by compound 48/80. In addition, mice administered MPC are protected from anti-DNP IgE-mediated PCA, one of the most important *in vivo* models of anaphylaxis in




Figure 5. Effect of MPC on the IL-6 secretion. PMA plus A23187-stimulated HMC-1 cells were incubated for 8 h in the absence or presence of MPC. IL-6 secreted into the medium is presented as the mean $\pm$ SEM of three independent experiments. * $p < 0.05$; significantly different from the PMA+A23187 value.

local allergic reaction. This finding suggests that MPC might be useful in the treatment of allergic skin reactions. Mast cell-derived cytokines, especially TNF- α and IL-6 have a critical biological role in the allergic reaction. Mast cells are a principal source of TNF- α in human dermis, and degradation of mast cells in the dermal endothelium is abrogated by the anti-TNF- α antibody (Walsh et al. 1991). IL-6 is also produced from mast cells and its local accumulation is associated with a PCA reaction (Mican et al. 1992). These reports indicate that reduction of pro-inflammatory cytokines from mast cell is a one of the key indicator of reduced allergic symptom. In the present study, MPC inhibited the secretion of TNF- α and IL-6 in PMA plus A23187-stimulated HMC-1 cells. This result suggests that the anti-allergic effect of MPC results from its reduction of TNF- α and IL-6 release from mast cells.

In conclusion, the results obtained in the present study provide evidence that MPC contributes importantly to the prevention or treatment of mast cell-mediated allergic diseases. In addition, it suggests that MPC may contain compounds with actions that inhibit mast cell-mediated allergic reactions *in vivo* and *in vitro*. The effort to identify active components from MPC in the immediate-type allergic reaction is ongoing in our laboratory.

Acknowledgements

This work was supported by Thailand Research Fund MRG4980137. The authors are grateful to Y.N. He and H.L. Liang at Kunming Institute of Botany (KIB), Chinese Academy of Sciences, for measuring NMR and MS data, respectively.

References

- Alber G, Miller L, Jelsema CL, Varin-Blank N, Metzger H. 1991. Structure-function relationships in the mast cell high affinity receptor for IgE. Role of the cytoplasmic domains and of the beta subunit. *J Biol Chem* 266:22613–22620.
- Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH. 1993. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. *J Immunol* 151:3853–3865.
- Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson SD, Dvorak AM, Galli SJ, Dorf ME. 1989. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. *J Exp Med* 170:245–257.
- Chahdi A, Fraundorfer PF, Beaven MA. 2000. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GPT-binding proteins. *J Pharmacol Exp Ther* 292:122–130.
- Church MK, Levi-Schaffer F. 1997. The human mast cell. *J Allergy Clin Immunol* 99:155–160.
- Ennis M, Pearce FL, Weston PM. 1980. Some studies on the release of histamine from mast cells stimulated with polylysine. *Br J Pharmacol* 70:329–334.
- Galli SJ, Gorgon JR, Wershil BK. 1991. Cytokine production by mast cells and basophils. *Curr Opin Immunol* 3:865–872.
- Katayama S, Shionoya H, Ohtake S. 1978. A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. *Microbiol Immunol* 22:89–101.
- Lagunoff D, Martin TW, Read G. 1983. Agents that release histamine from mast cells. *Annu Rev Pharmacol Toxicol* 23:331–351.
- Metcalf DD, Kaliner M, Donlon MA. 1981. The mast cell. *Crit Rev Immunol* 3:23–27.
- Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R. 1986. The receptor with high affinity for immunoglobulin E. *Annu Rev Immunol* 4:419–470.

- Mican JA, Arora N, Burd PR, Metcalfe DD. 1992. Passive cutaneous anaphylaxis in mouse skin is associated with local accumulation of interleukin-6 mRNA and immunoreactive interleukin-6 protein. *J Allergy Clin Immunol* 90:815–824.
- Moller A, Henz BM, Grutzkau A, Lippert U, Aragane Y, Schwarz T, Kruger-Krasagakes S. 1998. Comparative cytokine gene expression regulation and release by human mast cells. *Immunology* 93:289–295.
- Mousli MC, Bronner C, Bockaert J, Rouot B, Landry Y. 1990a. Interaction of substance P, compound 48/80 and mastoparan with a subunit C-terminal of G protein. *Immunol Lett* 25:355–358.
- Mousli MC, Bronner C, Landry Y, Bockaert J, Rouot B. 1990b. Direct activation of GTP-binding regulatory proteins (G proteins) by substance P and compound 48/80. *FEBS Lett* 259:260–262.
- Petersen LJ, Mosbech H, Skov P. 1996. Allergen-induced histamine release in intact human skin *in vivo* assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. *J Allergy Clin Immunol* 97:672–679.
- Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. 1989. Mast cell lines produce lymphokines in response to crosslinkage of Fc epsilon RI or to calcium ionophores. *Nature* 339:64–67.
- Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Peterson E, Slymen DJ, Salmon SE. 1986. Raised serum levels of tumor necrosis factor in parasitic infections. *Lancet* 13:1364–1365.
- Shore PA, Burkhalter A, Cohn VH. 1959. A method for fluorometric assay of histamine in tissues. *J Pharmacol Exp Ther* 127:182–186.
- Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, Kraft D, Lechner K, Bettelheim P, Valent P. 1993. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. *Exp Hematol* 21:1271–1275.
- Taechowisan T, Lumyong S. 2003. Activity of endophytic actinomycetes from roots of *Zingiber officinale* and *Alpinia galanga* against phytopathogenic fungi. *Ann Microbiol* 53:291–298.
- Taechowisan T, Peberdy JF, Lumyong S. 2003. Isolation of endophytic actinomycetes from selected plants and their antifungal activity. *World J Microbiol Biotechnol* 19:381–385.
- Taechowisan T, Lu C, Shen Y, Lumyong S. 2005. Secondary metabolites from endophytic *Streptomyces aureofaciens* CMUAc130 and their antifungal activity. *Microbiology* 151:1691–1695.
- Taechowisan T, Tuntiwachwuttikul P, Lu C, Shen Y, Lumyong S, Taylor WC. 2007. Anti-inflammatory activity of 4-arylcoumarins from endophytic *Streptomyces aureofaciens* CMUAc130 in murine macrophage RAW264.7 cells. *Immunol Invest* 36:203–211.
- Tasaka K, Mio M, Okamoto M. 1986. Intracellular calcium release induced by histamine releasers and its inhibition by some anti-allergic drugs. *Ann Allergy* 56:464–469.
- Thomson DS, Evans DP. 1973. Inhibition of immediate hypersensitivity reactions by disodium cromoglycate. Requirements for activity in two laboratory models. *Clin Exp Immunol* 13:537–544.
- Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. 1991. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. *Proc Natl Acad Sci USA* 88:4220–4224.
- Wells E, Mann J. 1983. Phosphorylation of a mast cell protein in response to treatment with anti-allergic compounds. *Biochem Pharmacol* 32:837–842.